北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial
作者: Wong, Ka Sing Lawrence1; Hu, Dai Yi2; Oomman, Abraham3; Tan, Ru-San4; Patel, Manesh R.5; Singer, Daniel E.7,8; Breithardt, Guenter9; Mahaffey, Kenneth W.5; Becker, Richard C.5; Califf, Robert6; Fox, Keith A. A.10,11; Berkowitz, Scott D.12; Hacke, Werner13; Hankey, Graeme J.14; Executive Steering Comm; ROCKET AF Study Investigators
关键词: atrial fibrillation ; Far East ; rivaroxaban ; stroke
刊名: STROKE
发表日期: 2014-06-01
DOI: 10.1161/STROKEAHA.113.002968
卷: 45, 期:6, 页:1739-+
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Clinical Neurology ; Peripheral Vascular Disease
研究领域[WOS]: Neurosciences & Neurology ; Cardiovascular System & Cardiology
关键词[WOS]: ATRIAL-FIBRILLATION ; JAPANESE PATIENTS ; WARFARIN ; ANTICOAGULATION ; THERAPY ; CHINA ; PHARMACODYNAMICS ; PHARMACOKINETICS ; INTENSITY ; SUBTYPES
英文摘要:

Background and Purpose-In Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial, rivaroxaban was noninferior to dose-adjusted warfarin in preventing stroke or systemic embolism among patients with nonvalvular atrial fibrillation at moderate to high stroke risk. Because of differences in patient demographics, epidemiology, and stroke risk management in East Asia, outcomes and relative effects of rivaroxaban versus warfarin were assessed to determine consistency among East Asians versus other ROCKET AF participants.

Methods-Baseline demographics and interaction of treatment effects of rivaroxaban and warfarin among patients within East Asia and outside were assessed.

Results-A total of 932 (6.5%) ROCKET AF participants resided in East Asia. At baseline, East Asians had lower weight, creatinine clearance, and prior vitamin K antagonist use; higher prevalence of prior stroke; and less congestive heart failure and prior myocardial infarction than other participants. Despite higher absolute event rates for efficacy and safety outcomes in East Asians, the relative efficacy of rivaroxaban (20 mg once daily; 15 mg once daily for creatinine clearance of 30-49 mL/min) versus warfarin with respect to the primary efficacy end point (stroke/systemic embolism) was consistent among East Asians and non-East Asians (interaction P=0.666). Relative event rates for the major or nonmajor clinically relevant bleeding in patients treated with rivaroxaban and warfarin were consistent among East Asians and non-East Asians (interaction P=0.867).

Conclusions-Observed relative efficacy and safety of rivaroxaban versus warfarin were similar among patients within and outside East Asia. Rivaroxaban, 20 mg once daily, is an alternative to warfarin for stroke prevention in East Asians with nonvalvular atrial fibrillation.

语种: 英语
项目资助者: Janssen Research and Development, LLC ; Bayer HealthCare Pharmaceuticals
WOS记录号: WOS:000337090700034
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/64784
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Harvard Univ, Sch Med, Boston, MA USA
2.Univ Hosp Munster, Dept Cardiovasc Med, Munster, Germany
3.Bayer HealthCare Pharmaceut, Montville, NJ USA
4.Heidelberg Univ, Dept Neurol, Heidelberg, Germany
5.Apollo Hosp, Dept Cardiol, Madras, Tamil Nadu, India
6.Natl Heart Ctr, Singapore, Singapore
7.Massachusetts Gen Hosp, Dept Epidemiol, Boston, MA 02114 USA
8.Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
9.Peking Univ, Peoples Hosp, Ctr Heart, Beijing 100871, Peoples R China
10.Duke Univ, Med Ctr, Dept Med, Div Cardiol,Duke Clin Res Inst, Durham, NC 27710 USA
11.Duke Univ, Med Ctr, Dept Med, Div Cardiol,Duke Translat Med Inst, Durham, NC 27710 USA
12.Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
13.Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland
14.Univ Western Australia, Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6009, Australia

Recommended Citation:
Wong, Ka Sing Lawrence,Hu, Dai Yi,Oomman, Abraham,et al. Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial[J]. STROKE,2014,45(6):1739-+.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Wong, Ka Sing Lawrence]'s Articles
[Hu, Dai Yi]'s Articles
[Oomman, Abraham]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Wong, Ka Sing Lawrence]‘s Articles
[Hu, Dai Yi]‘s Articles
[Oomman, Abraham]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace